BUZZ-Transition Therapeutics Inc: Alzheimer's drug fails study
** Drug developer's shares down 20 pct at $7.30 premarket
** Says mid-stage study of its experimental neuropshychiatric drug, ELND005, did not meet main goal of significant reduction in agitation and aggression
** Study was testing patients with mild to severe Alzheimer's disease
** Says external advisory panel will be consulted to decide future of drug
** Up to Tuesday's close, stock had risen 27 pct in 12 months
© Thomson Reuters 2017 All rights reserved.